

## Declaration of Interests Register

**TA Committee C**

**Publication Date: 21/10/2020**

**Topic: Nivolumab for previously treated squamous non-small-cell lung cancer (CDF review TA483) [ID1559]**

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Richard Nicholas	TAC Committee Member (C)	Indirect – financial	Richard has received a consultancy fee in an unrelated disease area from Novartis Pharmaceuticals	Not specified	Feb 2020	Not specified	It was agreed that this declaration would not prevent Richard Nicholas from participating in this section of the meeting.
Michael Chambers	TAC Committee Member (C)	Indirect - financial	Michael received consultancy fee from a comparator company, Roche Products in an unrelated disease area	Not specified	Feb 2020	Not specified	It was agreed that this declaration would not prevent Michael Chambers from participating in this section of the meeting.